NEW YORK (GenomeWeb News) – Illumina has appointed Elizabeth Brady to be VP of global supply chain and Emily Winn-Deen to be VP of diagnostics development.
Brady, who formerly was a VP at Boston Scientific, will run global sourcing, planning, logistics, and distribution operations. Winn-Deen previously was VP of Genetics and Oncology R&D at Cepheid, and she was involved in diagnostics at Roche Molecular Systems, Applera, Oncor, and Bayer Diagnostics.
Illumina has granted Brady an option to purchase 120,000 shares of Illumina's common stock, and Winn-Deen an option to buy 112,000 shares.
Expression Analysis this week announced two additions to its scientific management team. Patrick Hurban has been named vice president of research and development at the Durham, NC-based firm, while Louise Grant has been appointed director of operations.
Hurban holds a PhD in human genetics from the University of Utah School of Medicine and did his postdoc at Stanford University School of Medicine in the departments of developmental biology and biochemistry. Grant was most recently microbiology program director at BioMérieux and was responsible for R&D, technical support, and product management at Becton Dickinson.
Katherine Richardson has joined Transgenomic as technical director for laboratory services, where she will be responsible for managing the day-to-day operations of the company's services labs. She comes to Transgenomic from OSI Pharmaceuticals, where she did research in molecular biology and development in the area of oncology.
Stéphane Bancel, CEO of BioMérieux, will join the board of directors of Knome, following BioMérieux's recent $5 million equity investment in the company.
High Throughput Genomics said this week that Lee Hartwell and Timothy Yeatman have joined the company's scientific advisory board.
Hartwell is president and director of the Fred Hutchinson Cancer Research Center. Yeatman is executive vice president, co-founder, and chief scientific officer of M2Gen.
Vermillion this week announced the appointment of Sandra Gardiner as vice president and chief financial officer. Gardiner was previously at Bend Research where she was CFO and a member of its board. From 2004 to 2008, Gardiner was CFO and corporate secretary of Lipid Sciences.
In a document filed with the US Securities and Exchange Commission, Vermillion said her annual base salary will be at least $240,000. Gardiner will also be eligible for a bonus of up to 40 percent of her salary based on performance goals to be determined by the CEO or Vermillion's board.
Polyplus-transfection has named Mark Bloomfield to serve as CEO. He will replace Frederic Perraud, who will remain with the firm as COO and deputy CEO. The firm is planning to launch new reagents and solutions for cell transfection applications, and to commercialize its ZNA technology. Bloomfield has spent 15 years in biotechnology and analytical instruments sales and management, including stints at Agilent Technologies, Thermo Electron, and at Applied Biosystems' Molecular and Cell Biology Business Unit.
Galapagos has appointed Ronald Brus to its board of directors. Brus, who was named to serve on the board until 2014, is president and CEO of Crucell. Brus previously was product planning physician at Forest Laboratories, and he was medical director for Zambon. He already served on Galapagos' board between 2000 and 2005.
Nanotechnology company Arrowhead Research Corporation has appointed Andrew von Eschenbach to serve on its scientific advisory board. Von Eschenbach formerly was commissioner of the US Food and Drug Administration under President George W. Bush, and he formerly was director of the National Cancer Institute.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.